Pfizer, Astellas secure expanded FDA approval for XTANDI

This article was originally published here

The latest approval means that XTANDI is indicated for the treatment of three distinct forms of advanced prostate cancer that include non-metastatic and metastatic castration-resistant prostate cancer (CRPC),

The post Pfizer, Astellas secure expanded FDA approval for XTANDI appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply